2 active not recruiting, 2 terminated, 2 withdrawn, 1 recruiting. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Active not recruiting 2, Terminated 2, Withdrawn 2, Recruiting 1 |
Follow ozanimod: new trials by email Literature Review of ozanimod trials Research Report on ozanimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study Ozanimod Oral Capsule - Ulcerative Colitis | Phase 4 | Withdrawn | Geert D'Haens | 2024-08-01 | 2024-09-19 | |
| Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod Ozanimod - Relapsing Multiple Sclerosis | Phase 4 | Recruiting | University of Colorado, Denver | 100 | 2024-07-29 | 2025-09-18 |
| Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS Ozanimod - Multiple Sclerosis | Phase 4 | Withdrawn | The University of Texas at Dallas | 2024-06-01 | 2024-08-09 | |
| A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis BMS-986374 - Relapsing Multiple Sclerosis | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 84 | 2024-05-15 | 2025-04-16 |
| Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis. Ozanimod Oral Capsule - Multiple Sclerosis | Phase 4 | Terminated | I.R.C.C.S. Fondazione Santa Lucia | 30 | 2023-01-31 | 2025-01-15 |
| An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice Ozanimod - Colitis, Ulcerative | Phase 4 | Terminated | Bristol-Myers Squibb | 139 | 2022-12-16 | 2026-02-10 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
Colitis, Ulcerative (2) · Multiple Sclerosis (2) · Inflammatory Bowel Diseases (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Bristol-Myers Squibb (2) · Geert D'Haens (1) · I.R.C.C.S. Fondazione Santa Lucia (1) · The Cleveland Clinic (1) · The University of Texas at Dallas (1) · University of Colorado, Denver (1)
United States (4) · China (1) · Italy (1) · United Kingdom (1)
Bart Rypma, PhD (1) · Daniel Ontaneda, MD, MSc (1) · Enrique Alvarez, MD/PhD (1) · Geert DHaens (1) · Nikos Evangelou, MD, DPhil (1)
2023 (1)